TL;DR
Get home appliances delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Noom has announced a new GLP-1Rx program that offers prescription weight-loss medications alongside its behavioral support platform. The program aims to provide personalized treatment and ongoing support, with medications starting at $99 for eligible users. The initiative marks a significant expansion of Noom’s health offerings.
Noom has officially launched its GLP-1Rx program, offering prescription medications such as Ozempic® and Zepbound® combined with its behavioral support platform. This move aims to provide a comprehensive, personalized approach to weight management, making medication more accessible to users who qualify.
The program is developed by medical professionals and integrates licensed clinicians, behavior change coaches, and community support to help users achieve sustainable weight loss. Participants can take a quiz to determine eligibility, connect with a qualified clinician, and start a customized treatment plan that includes medication if deemed appropriate. Medications are available starting at $99 for those who qualify, regardless of insurance coverage, with brand-name options like Ozempic® and Zepbound® included.
A key feature of the program is the GLP-1 Companion, a digital tool providing ongoing support and resources for medication management, side effects, nutrition, and body composition tracking. According to Greatist, users who engage more with the companion tend to see approximately 25% greater weight loss. The program emphasizes a combined approach of medication and psychological support to promote lasting healthy habits and weight loss success.
Implications of Noom’s GLP-1Rx Program for Weight Management
This initiative signifies a major shift in how weight loss programs are delivered, integrating prescription medications directly into a behavioral health platform. It could increase access to clinically proven weight-loss drugs for individuals who may not have considered or been able to afford them previously. The program’s emphasis on ongoing support aims to improve long-term outcomes, potentially setting new standards in digital health and weight management. However, the long-term effectiveness and safety of combining medication with behavioral support at scale remain under evaluation.
As an affiliate, we earn on qualifying purchases.
Background on Noom’s Entry into Pharmacological Weight Loss
Noom has long been recognized for its psychology-based approach to weight management, helping millions develop healthier habits. The company’s entry into medication-assisted weight loss aligns with broader industry trends following the approval and increased use of GLP-1 receptor agonists like Ozempic® for obesity treatment. Prior to this, such medications were primarily accessed through healthcare providers and insurance plans. Noom’s new program aims to democratize access by offering medications at a fixed starting price, with integrated behavioral support to enhance effectiveness.
“Noom’s new GLP-1Rx program combines medication with its proven behavioral approach, offering a personalized pathway to sustainable weight loss.”
— an anonymous researcher
Zepbound prescription weight loss drugs
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Uncertainties Surrounding Program Efficacy and Accessibility
It is not yet clear how many users will qualify for the medication component or how the program will be adopted across diverse populations. Long-term data on the effectiveness of combining Noom’s behavioral support with GLP-1 medications at scale is still emerging. Additionally, questions remain about insurance coverage, potential side effects, and regulatory oversight of the program’s medical components.
GLP-1 receptor agonist supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Next Steps for Noom’s GLP-1Rx Program and Industry Impact
Noom is expected to monitor user outcomes closely and potentially publish data on the program’s effectiveness. The company may expand access or refine its offerings based on initial feedback. Industry observers will watch whether this integrated approach influences other digital health platforms and traditional healthcare providers to adopt similar models, potentially reshaping weight management services.
digital weight management support tools
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Who is eligible for Noom’s GLP-1Rx program?
Eligibility is determined through a quiz and clinical assessment; those who qualify will be connected with a licensed clinician to develop a personalized treatment plan.
What medications are included in the program?
The program offers brand-name medications such as Ozempic® and Zepbound®, starting at $69 plus out-of-pocket costs depending on insurance coverage.
Can I access the medications without a prescription?
No, medications are only available through the program with a prescription from a qualified clinician following an assessment.
How does the GLP-1 Companion support users?
The GLP-1 Companion provides ongoing resources, symptom management guidance, nutrition plans, body scans, and messaging with clinicians to optimize medication use and support healthy habits.
Will this program be covered by insurance?
While medications start at $99 for qualifying users, coverage varies; some out-of-pocket costs may apply depending on individual insurance plans.
Source: Greatist
Fall yard work Picks
leaf blowers
As an affiliate, we earn on qualifying purchases.
